<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01964807</url>
  </required_header>
  <id_info>
    <org_study_id>P0052956</org_study_id>
    <secondary_id>P50CA180890</secondary_id>
    <secondary_id>136316</secondary_id>
    <nct_id>NCT01964807</nct_id>
  </id_info>
  <brief_title>Cardiovascular Assessment of the Effects of Tobacco and Nicotine Delivery Products</brief_title>
  <official_title>Cardiovascular Assessment of the Effects of Tobacco and Nicotine Delivery Products</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Food and Drug Administration (FDA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overarching goal of this project is to develop a panel of cardiovascular risk biomarkers&#xD;
      that can detect differences in the cardiovascular safety of various tobacco products, whether&#xD;
      conventional, new or emerging, in order to help the FDA with the task of regulating them.&#xD;
      This will be achieved through 4 aims:&#xD;
&#xD;
      Aim 1: Determine the relative contributions of nicotine and combustion products to the&#xD;
      cardiovascular risk of active cigarette smoking.&#xD;
&#xD;
      Aim 2: Determine which cardiovascular risk biomarkers are affected by exposure to secondhand&#xD;
      smoke.&#xD;
&#xD;
      Aim 3: Determine the cardiovascular risk of smokeless tobacco use.&#xD;
&#xD;
      Aim 4: Determine the cardiovascular risk of electronic cigarettes and the respective&#xD;
      contributions of nicotine and electronic cigarette vapor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cigarette smoking is a major cause of cardiovascular disease (CVD).1 In contrast, the&#xD;
      cardiovascular risks of other popular tobacco products (smokeless tobacco), new tobacco&#xD;
      products ( e-cigarettes) and proposed products (reduced nicotine cigarettes) are not&#xD;
      adequately understood. The FDA will need information about the cardiovascular safety of these&#xD;
      products to inform their regulatory decisions. While long-term clinical outcome studies of&#xD;
      the cardiovascular risks of these tobacco products would be optimal, they take too long to&#xD;
      provide the data that the FDA needs now. Disturbances in the function of vascular endothelium&#xD;
      (the lining of arteries, which plays an important role in regulating vascular function) and&#xD;
      the activation of the autonomic nervous system, as well as increased inflammation, oxidative&#xD;
      stress and propensity to thrombosis (clotting), are key mechanisms in the progression of CVD&#xD;
      and validated biomarkers of CVD risk. These biomarkers form the basis for our model to assess&#xD;
      the CVD risks of tobacco product use and secondhand smoke exposure. We will conduct&#xD;
      controlled, short-term exposures of human subjects to test products that provide a wide range&#xD;
      of nicotine, particle, and other cardiovascular toxin concentrations to determine how these&#xD;
      components associated with tobacco use adversely affect cardiovascular risk.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flow-mediated Dilation of the Brachial Artery</measure>
    <time_frame>up to 3 hours after use of tobacco product</time_frame>
    <description>Vascular function as measured by Flow-mediated Dilation of the Brachial Artery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart Rate Variability (HRV)</measure>
    <time_frame>up to 3 hours after use of product.</time_frame>
    <description>HRV refers to variation in the intervals between consecutive heart beats. Low HRV predicts poor prognosis and increased mortality in patients with cardiovascular disease and in apparently healthy subjects</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Clot strength and plasma levels of interleukin-6 (IL-6) and 8-isoprostane</measure>
    <time_frame>up to 3 hours after use of product.</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Adverse Effect of Other Agents Primarily Affecting the Cardiovascular System, Initial Encounter</condition>
  <arm_group>
    <arm_group_label>Cigarette smokers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will smoke 1 cigarette, National Institute of Drug Abuse (NIDA) test type with 16.6 mg nicotine; 1 cigarette, NIDA test type with &lt;0.45 mg nicotine; perform sham smoking by puffing on a drinking straw. Each intervention will last 10 minutes, and each will take place one time, on one of 3 study visits, in random order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nonsmokers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will undergo secondhand cigarette smoke (SHS) exposure and conditioned, filtered air exposure. Each intervention will last 180 minutes, and each will take place one time, on one of 2 study visits, in random order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Smokeless tobacco users</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will use 1 pouch of commercially available moist oral snuff and will chew gum (sham moist snuff). Each intervention will last 30 minutes, and each will take place one time, on one of 2 study visits, in random order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>e-cigarette users</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will use one electronic cigarette with 18 mg/ml nicotine, one electronic cigarette with no nicotine, and will perform sham smoking by puffing on a drinking straw. Each intervention will last 10 minutes, and each will take place one time, on one of 3 study visits, in random order.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cigarette, NIDA test type with 16.6 mg nicotine</intervention_name>
    <description>Smoke a single cigarette for up to 10 minutes</description>
    <arm_group_label>Cigarette smokers</arm_group_label>
    <other_name>Cigarette</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cigarette, NIDA test type with &lt;0.45 mg nicotine</intervention_name>
    <description>Smoke a single low-nicotine cigarette for up to 10 minutes</description>
    <arm_group_label>Cigarette smokers</arm_group_label>
    <other_name>Cigarette</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electronic cigarette with 18 mg/ml nicotine</intervention_name>
    <description>Use electronic cigarette with 18 mg/ml nicotine for 30 minutes</description>
    <arm_group_label>e-cigarette users</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electronic Cigarette with no nicotine</intervention_name>
    <description>Use electronic cigarette with no nicotine for 30 minutes</description>
    <arm_group_label>e-cigarette users</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Moist snuff</intervention_name>
    <description>Use moist snuff for 30 minutes</description>
    <arm_group_label>Smokeless tobacco users</arm_group_label>
    <other_name>commercially available moist oral snuff</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham Smoking</intervention_name>
    <description>Sham smoking or e-cigarette use consists of puffing on a drinking straw for 10 minutes</description>
    <arm_group_label>Cigarette smokers</arm_group_label>
    <arm_group_label>e-cigarette users</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Secondhand cigarette smoke (SHS)</intervention_name>
    <description>180-minute exposure to SHS generated by controlled dilution of smoke from machine-smoked cigarettes</description>
    <arm_group_label>Nonsmokers</arm_group_label>
    <other_name>Environmental Tobacco Smoke (ETS)</other_name>
    <other_name>ETS</other_name>
    <other_name>SHS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conditioned, filtered air</intervention_name>
    <description>Exposure to conditioned, filtered air for 180 minutes</description>
    <arm_group_label>Nonsmokers</arm_group_label>
    <other_name>Clean, filtered, temperature and humidity controlled air</other_name>
    <other_name>Negative control for SHS exposure</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham Moist Snuff</intervention_name>
    <description>Chew gum for 30 minutes</description>
    <arm_group_label>Smokeless tobacco users</arm_group_label>
    <other_name>Chewing gum</other_name>
    <other_name>Negative control for moist oral snuff use</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All Groups: Age 18-50&#xD;
&#xD;
          -  Can tolerate withholding their medications for two weeks at a time&#xD;
&#xD;
          -  Group 1: Active smokers&#xD;
&#xD;
          -  Group 2: Nonsmokers&#xD;
&#xD;
          -  Group 3: Active users of smokeless tobacco&#xD;
&#xD;
          -  Group 4: Active users of electronic cigarettes&#xD;
&#xD;
          -  Additional Inclusion Criteria for E-Cigarette Users:&#xD;
&#xD;
          -  Currently use ofe-cigarettes &gt; 5 times a day&#xD;
&#xD;
          -  Has used e-cigarettes for &gt;3 months&#xD;
&#xD;
          -  Additional Inclusion Criteria for Active Smokers: Currently smoke &gt;5 cigarettes per&#xD;
             day â‰¥ 1 pack year&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exclusion Criteria for all subjects&#xD;
&#xD;
          -  Physician diagnosis of:&#xD;
&#xD;
          -  asthma&#xD;
&#xD;
          -  heart disease&#xD;
&#xD;
          -  hypertension&#xD;
&#xD;
          -  dyslipidemia&#xD;
&#xD;
          -  thyroid disease&#xD;
&#xD;
          -  diabetes&#xD;
&#xD;
          -  renal or liver impairment&#xD;
&#xD;
          -  glaucoma.&#xD;
&#xD;
          -  Unstable psychiatric condition (such as current major depression, history of&#xD;
             schizophrenia or bipolar disorder)&#xD;
&#xD;
          -  current use of more than two psychiatric medications&#xD;
&#xD;
          -  Pregnancy or breastfeeding (by history)&#xD;
&#xD;
          -  Alcohol, opiate, cocaine, amphetamine or methamphetamine dependence within the past 5&#xD;
             years&#xD;
&#xD;
          -  BMI &gt; 35 and &lt; 18&#xD;
&#xD;
          -  Current opiate, cocaine, amphetamine or methamphetamine use (by history or urine test)&#xD;
&#xD;
          -  Occupational exposure to smoke, dusts and fumes&#xD;
&#xD;
          -  Concurrent participation in another clinical trial&#xD;
&#xD;
          -  Unable to communicate in English&#xD;
&#xD;
          -  Additional Exclusion Criteria for Active Smokers:&#xD;
&#xD;
          -  Unable to hold marijuana for 1 week prior to each study visit.&#xD;
&#xD;
          -  Exhaled carbon monoxide (CO) &lt;10 ppm at each visit&#xD;
&#xD;
          -  Negative salivary cotinine test using a rapid-read, over the counter test with 30&#xD;
             ng/ml cutoff&#xD;
&#xD;
          -  Additional Exclusion Criteria for Nonsmokers:&#xD;
&#xD;
          -  More than 1 pack year smoking history&#xD;
&#xD;
          -  Quit smoking &lt; 5 years ago&#xD;
&#xD;
          -  Ever a daily marijuana smoker&#xD;
&#xD;
          -  Smoked anything within the last 3 months&#xD;
&#xD;
          -  Additional Inclusion Criteria for Smokeless Tobacco Users:&#xD;
&#xD;
          -  Use of moist oral snuff &gt; 5 times a day&#xD;
&#xD;
          -  Has used moist oral snuff for at least 0.5 years&#xD;
&#xD;
          -  Additional Exclusion Criteria for Smokeless Tobacco Users:&#xD;
&#xD;
          -  Current smoker&#xD;
&#xD;
          -  Quit smoking &lt; 0.5 years ago&#xD;
&#xD;
          -  Additional Exclusion Criteria for E-Cigarette Users:&#xD;
&#xD;
          -  Current use of other tobacco products&#xD;
&#xD;
          -  Unable to hold marijuana for 1 week prior to each study visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Ganz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 4, 2013</study_first_submitted>
  <study_first_submitted_qc>October 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2013</study_first_posted>
  <last_update_submitted>November 13, 2020</last_update_submitted>
  <last_update_submitted_qc>November 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiovascular</keyword>
  <keyword>tobacco</keyword>
  <keyword>cigarettes</keyword>
  <keyword>secondhand cigarette smoke</keyword>
  <keyword>SHS</keyword>
  <keyword>smokeless tobacco</keyword>
  <keyword>chewing tobacco</keyword>
  <keyword>snus</keyword>
  <keyword>electronic cigarettes</keyword>
  <keyword>vapor</keyword>
  <keyword>particles</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>flow-mediated dilation (FMD)</keyword>
  <keyword>FMD</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Information might be disclosed as part of study activities to the FDA</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

